GlassScriptPhysician profile
William S Taddonio
NPI 1932191186
$8,296.30
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2020: $974 · 2021: $2,418 · 2022: $1,640 · 2023: $1,299 · 2024: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,529.07 | 2019-2023 | Breztri, Farxiga |
| Abbvie INC. | $1,405.16 | 2019-2024 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,237.32 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $766.76 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $459.13 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $358.20 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.89 | 2019-2024 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $211.05 | 2019-2022 | |
| Pfizer INC. | $193.72 | 2019-2023 | |
| Amarin Pharma, INC. | $186.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $182.45 | 2019-2023 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $155.71 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.07 | 2019-2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $115.87 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $96.27 | 2019-2020 | |
| Sanofi Pasteur INC. | $89.68 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $87.18 | 2022-2023 | Rexulti, Abilify Maintena |
| Kowa Pharmaceuticals America, INC. | $70.18 | 2019-2021 | |
| Lundbeck LLC | $64.83 | 2022-2024 | Rexulti |
| Almatica Pharma LLC | $61.07 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $52.58 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.09 | 2019 | |
| Esperion Therapeutics, INC. | $49.78 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $45.89 | 2019 | |
| Abbott Laboratories | $41.68 | 2022-2023 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $41.63 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.30 | 2023 | |
| Avanir Pharmaceuticals, INC. | $30.04 | 2019 | |
| Philips North America LLC | $29.45 | 2020-2021 | |
| Horizon Therapeutics Plc | $26.36 | 2019-2020 | |
| Exact Sciences Corporation | $21.58 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $19.98 | 2022 | |
| Shire North American Group INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Taddonio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.